Autoimmune polyendocrine syndrome type 3, characterized by autoimmune thyroid disease, type 1 diabetes mellitus, and isolated ACTH deficiency, developed during adjuvant nivolumab treatment

Mayumi Takata; Motoo Nomura; Kentaro Yamamura; Manabu Muto; Takaya Komori; Atsushi Otsuka; Kenji Kabashima

doi:10.1111/ajco.13573

Autoimmune polyendocrine syndrome type 3, characterized by autoimmune thyroid disease, type 1 diabetes mellitus, and isolated ACTH deficiency, developed during adjuvant nivolumab treatment

Asia Pac J Clin Oncol. 2022 Aug;18(4):481-482. doi: 10.1111/ajco.13573. Epub 2021 Apr 18.

Authors

Mayumi Takata¹, Motoo Nomura², Kentaro Yamamura^{1

3}, Manabu Muto², Takaya Komori¹, Atsushi Otsuka¹, Kenji Kabashima¹

Affiliations

¹ Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
² Department of Medical Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
³ Department of Dermato-Oncology Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.

PMID: 33870636
DOI: 10.1111/ajco.13573

Abstract

Autoimmune polyendocrine syndrome (APS) is one of the life-threatening immune-related adverse events (irAEs). We firstly report a case of APS induced by adjuvant nivolumab therapy. Clinicians should be aware of the potential risks of developing severe irAEs when applying adjuvant immunotherapy.

Publication types

Case Reports
Letter

MeSH terms

Adrenocorticotropic Hormone / adverse effects
Adrenocorticotropic Hormone / deficiency
Diabetes Mellitus, Type 1* / chemically induced
Diabetes Mellitus, Type 1* / drug therapy
Endocrine System Diseases
Genetic Diseases, Inborn
Humans
Hypoglycemia
Nivolumab / adverse effects
Polyendocrinopathies, Autoimmune* / chemically induced
Thyroid Diseases* / chemically induced

Substances

Nivolumab
Adrenocorticotropic Hormone

Supplementary concepts

ACTH Deficiency, Isolated